Oric Pharmaceuticals IncNASDAQ:ORIC
- LAST PRICE10.1400
- TODAY'S CHANGE (%)0.1400 (1.4000%)
- Bid / Lots10.1300/ 1
- Ask / Lots10.1500/ 2
- Open / Previous Close10.2700 / 10.0000
- Day Range
- 52 Week Range
- Volume100,026
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ORIC |
|---|---|---|
| 09:32 ET | 4013 | 10.29 |
| 09:36 ET | 100 | 10.21 |
| 09:38 ET | 20141 | 10.11 |
| 09:39 ET | 3258 | 10.06 |
| 09:41 ET | 300 | 10.095 |
| 09:45 ET | 300 | 10.045 |
| 09:48 ET | 3840 | 10.11 |
| 09:50 ET | 2508 | 10.255 |
| 09:52 ET | 100 | 10.26 |
| 09:54 ET | 1797 | 10.14 |
| 09:57 ET | 898 | 10.14 |
| 09:59 ET | 1062 | 10.2 |
| 10:01 ET | 1418 | 10.29 |
| 10:03 ET | 200 | 10.315 |
| 10:06 ET | 200 | 10.34 |
| 10:08 ET | 100 | 10.31 |
| 10:10 ET | 300 | 10.33 |
| 10:12 ET | 100 | 10.305 |
| 10:14 ET | 100 | 10.34 |
| 10:15 ET | 100 | 10.31 |
| 10:17 ET | 1400 | 10.3475 |
| 10:19 ET | 100 | 10.34 |
| 10:21 ET | 500 | 10.285 |
| 10:24 ET | 200 | 10.25 |
| 10:28 ET | 100 | 10.225 |
| 10:30 ET | 200 | 10.24 |
| 10:33 ET | 500 | 10.26 |
| 10:39 ET | 200 | 10.32 |
| 10:42 ET | 600 | 10.29 |
| 10:44 ET | 100 | 10.28 |
| 10:46 ET | 100 | 10.27 |
| 10:48 ET | 986 | 10.3 |
| 10:50 ET | 527 | 10.28 |
| 10:51 ET | 796 | 10.3 |
| 10:53 ET | 600 | 10.33 |
| 10:55 ET | 200 | 10.32 |
| 10:57 ET | 425 | 10.23 |
| 11:02 ET | 300 | 10.245 |
| 11:04 ET | 400 | 10.25 |
| 11:06 ET | 300 | 10.24 |
| 11:08 ET | 100 | 10.24 |
| 11:09 ET | 200 | 10.29 |
| 11:11 ET | 100 | 10.295 |
| 11:15 ET | 100 | 10.295 |
| 11:18 ET | 200 | 10.31 |
| 11:20 ET | 900 | 10.31 |
| 11:26 ET | 100 | 10.32 |
| 11:27 ET | 100 | 10.32 |
| 11:29 ET | 400 | 10.32 |
| 11:31 ET | 1000 | 10.35 |
| 11:36 ET | 600 | 10.37 |
| 11:38 ET | 100 | 10.365 |
| 11:40 ET | 1751 | 10.39 |
| 11:42 ET | 100 | 10.38 |
| 11:47 ET | 429 | 10.42 |
| 11:49 ET | 500 | 10.4 |
| 11:51 ET | 100 | 10.39 |
| 11:54 ET | 500 | 10.4 |
| 11:56 ET | 300 | 10.41 |
| 12:03 ET | 400 | 10.42 |
| 12:05 ET | 100 | 10.42 |
| 12:07 ET | 200 | 10.39 |
| 12:09 ET | 500 | 10.41 |
| 12:14 ET | 100 | 10.36 |
| 12:20 ET | 100 | 10.36 |
| 12:21 ET | 100 | 10.36 |
| 12:23 ET | 200 | 10.355 |
| 12:25 ET | 1118 | 10.38 |
| 12:27 ET | 661 | 10.38 |
| 12:32 ET | 251 | 10.38 |
| 12:34 ET | 200 | 10.38 |
| 12:36 ET | 567 | 10.37 |
| 12:38 ET | 200 | 10.375 |
| 12:48 ET | 496 | 10.39 |
| 12:50 ET | 200 | 10.385 |
| 12:56 ET | 300 | 10.375 |
| 12:57 ET | 400 | 10.35 |
| 12:59 ET | 550 | 10.315 |
| 01:03 ET | 200 | 10.315 |
| 01:06 ET | 200 | 10.315 |
| 01:12 ET | 100 | 10.32 |
| 01:14 ET | 200 | 10.31 |
| 01:15 ET | 200 | 10.3 |
| 01:17 ET | 100 | 10.29 |
| 01:21 ET | 450 | 10.1909 |
| 01:24 ET | 1200 | 10.22 |
| 01:26 ET | 100 | 10.205 |
| 01:28 ET | 300 | 10.19 |
| 01:32 ET | 400 | 10.17 |
| 01:39 ET | 370 | 10.15 |
| 01:42 ET | 200 | 10.15 |
| 01:46 ET | 200 | 10.15 |
| 01:50 ET | 100 | 10.18 |
| 01:51 ET | 600 | 10.17 |
| 01:53 ET | 300 | 10.17 |
| 01:57 ET | 700 | 10.16 |
| 02:00 ET | 271 | 10.14 |
Sep 18, 2024
DJ Oric Pharmaceuticals Price Target Maintained With a $21.00/Share by HC Wainwright & Co., from 1:42PM ET on Wednesday Sep 18, 2024 by Dow Jones
1:42PM ET on Wednesday Sep 18, 2024 by Dow Jones
Sep 10, 2024
DJ Oric Pharmaceuticals Price Target Maintained With a $20.00/Share by Wedbush, from 9:08AM ET on Tuesday Sep 10, 2024 by Dow Jones
9:08AM ET on Tuesday Sep 10, 2024 by Dow Jones
Sep 6, 2024
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4), from 4:30PM ET on Friday Sep 06, 2024 by Dow Jones
4:30PM ET on Friday Sep 06, 2024 by Dow JonesDJ Oric Pharmaceuticals Initiated at Buy by Stifel, from 11:39AM ET on Friday Sep 06, 2024 by Dow Jones
11:39AM ET on Friday Sep 06, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Oric Pharmaceuticals Inc | 705.4M | -5.8x | --- |
Olema Pharmaceuticals Inc | 710.1M | -5.9x | --- |
Scholar Rock Holding Corp | 689.1M | -3.9x | --- |
Savara Inc | 683.1M | -9.6x | --- |
MBX Biosciences Inc | 737.7M | -16.1x | --- |
Rapport Therapeutics Inc | 743.2M | 0.0x | --- |
Company Information
ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in improving patients' lives by overcoming resistance in cancer. It is developing a pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Its clinical-stage product candidates include ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens.
Contact Information
- Headquarters
- 240 E. Grand Ave, 2nd FloorSOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- 650-388-5600
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Richard Heyman
- President, Chief Executive Officer, Director
- Jacob Chacko
- Chief Financial Officer
- Dominic Piscitelli
- Chief Medical Officer
- Pratik Multani
- Independent Director
- Mardi Dier
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $705.4M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 70.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.11 |
EPS | $-1.76 |
Book Value | $4.08 |
P/E Ratio | -5.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
